B. Markman

900 total citations
20 papers, 688 citations indexed

About

B. Markman is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, B. Markman has authored 20 papers receiving a total of 688 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in B. Markman's work include Cancer Immunotherapy and Biomarkers (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Lung Cancer Treatments and Mutations (4 papers). B. Markman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Lung Cancer Treatments and Mutations (4 papers). B. Markman collaborates with scholars based in Australia, United States and Spain. B. Markman's co-authors include José Baselga, Violeta Serra, Marta Guzmán, Manuela Gili, Yasir H. Ibrahim, Sarai Rodríguez, Sharat Singh, Joaquı́n Arribas, Sarat Chandarlapaty and Michelangelo Russillo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

B. Markman

19 papers receiving 677 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Markman Australia 8 469 293 152 102 88 20 688
Elisabeth Llonch Switzerland 2 509 1.1× 214 0.7× 128 0.8× 94 0.9× 106 1.2× 2 651
Raul Ayala United States 9 483 1.0× 356 1.2× 253 1.7× 64 0.6× 69 0.8× 18 830
Haby Henary United States 14 376 0.8× 378 1.3× 199 1.3× 59 0.6× 68 0.8× 32 702
Michel Maira Switzerland 8 629 1.3× 269 0.9× 180 1.2× 124 1.2× 124 1.4× 12 837
P.N. Munster United States 12 307 0.7× 336 1.1× 119 0.8× 43 0.4× 72 0.8× 18 584
Rosalin Mishra United States 11 421 0.9× 345 1.2× 139 0.9× 58 0.6× 56 0.6× 20 724
Davide Torti Italy 12 418 0.9× 304 1.0× 116 0.8× 60 0.6× 77 0.9× 17 677
María Luisa Botero United States 5 538 1.1× 322 1.1× 176 1.2× 95 0.9× 129 1.5× 11 844
Lisa Malburg United States 9 493 1.1× 405 1.4× 181 1.2× 47 0.5× 98 1.1× 14 780
Lucia Trandafir Switzerland 11 280 0.6× 247 0.8× 272 1.8× 73 0.7× 61 0.7× 22 634

Countries citing papers authored by B. Markman

Since Specialization
Citations

This map shows the geographic impact of B. Markman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Markman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Markman more than expected).

Fields of papers citing papers by B. Markman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Markman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Markman. The network helps show where B. Markman may publish in the future.

Co-authorship network of co-authors of B. Markman

This figure shows the co-authorship network connecting the top 25 collaborators of B. Markman. A scholar is included among the top collaborators of B. Markman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Markman. B. Markman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Markman, B., Martin Gutierrez, James A. Henry, et al.. (2025). 916O Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors. Annals of Oncology. 36. S559–S560.
2.
Peters, Solange, Daniel C. Christoph, John K. Field, et al.. (2023). OA17.03 Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R). Journal of Thoracic Oncology. 18(11). S83–S83. 3 indexed citations
3.
4.
Fong, Peter C.C., Víctor Moreno, Sophia Frentzas, et al.. (2020). 535MO BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma. Annals of Oncology. 31. S468–S469. 1 indexed citations
5.
Girard, Nicolas, Rainer Fietkau, Marina Chiara Garassino, et al.. (2020). 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Annals of Oncology. 31. S805–S806. 2 indexed citations
6.
Desai, Jayesh, B. Markman, Michael Friedländer, et al.. (2019). Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study. Clinical Trials. CT084–CT084. 1 indexed citations
7.
Desai, Jayesh, B. Markman, Michael Friedländer, et al.. (2019). Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study. Cancer Research. 79(13_Supplement). CT084–CT084. 2 indexed citations
8.
Clarke, Jeffrey, Lillian L. Siu, Jean‐Pascal Machiels, et al.. (2019). Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors. Molecular Cancer Therapeutics. 18(12_Supplement). B057–B057. 16 indexed citations
9.
10.
11.
Yen, Chia-Jui, B. Markman, Yee Chao, et al.. (2017). Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC). Annals of Oncology. 28. iii54–iii54. 11 indexed citations
12.
Emens, Leisha A., John D. Powderly, Lawrence Fong, et al.. (2017). Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors. Cancer Research. 77(13_Supplement). CT119–CT119. 27 indexed citations
13.
Markman, B., Josep Tabernero, Ian E. Krop, et al.. (2012). Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Annals of Oncology. 23(9). 2399–2408. 115 indexed citations
14.
Serra, Violeta, Maurizio Scaltriti, Ludmila Prudkin, et al.. (2011). PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 30(22). 2547–2557. 433 indexed citations
15.
Markman, B., Carlos Gomez‐Roca, Andrés Cervantes, et al.. (2010). Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti- EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC).. Journal of Clinical Oncology. 28(15_suppl). 2522–2522. 6 indexed citations
16.
Macarulla, Teresa, B. Markman, & Josep Tabernero. (2010). Membrane receptors as targets for therapeutic approaches in colorectal cancer. 1 indexed citations
17.
LoRusso, Patricia, B. Markman, Josep Tabernero, et al.. (2009). A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3502–3502. 32 indexed citations
18.
19.
Papadopoulos, Kyriakos P., B. Markman, Josep Tabernero, et al.. (2008). A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3510–3510. 20 indexed citations
20.
Markman, B., P. LoRusso, Akash Patnaik, et al.. (2008). 216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors. European Journal of Cancer Supplements. 6(12). 68–69. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabeth Llonch Breakdown of academic impact, for papers by Raul Ayala Breakdown of academic impact, for papers by Haby Henary Breakdown of academic impact, for papers by Michel Maira Breakdown of academic impact, for papers by P.N. Munster Breakdown of academic impact, for papers by Rosalin Mishra Breakdown of academic impact, for papers by Davide Torti Breakdown of academic impact, for papers by María Luisa Botero Breakdown of academic impact, for papers by Lisa Malburg Breakdown of academic impact, for papers by Lucia Trandafir
Rankless by CCL
2026